NTLA (Intellia Therapeutics) Total Liabilities: $137.84 Mil (As of Mar. 2026)

What is Intellia Therapeutics Total Liabilities?

Intellia Therapeutics NTLA +1.89% 71 Total Liabilities is $137.84 Mil as of Mar. 2026. GuruFocus rates NTLA with a GF Score™ of 71/100 and a GF Value™ of $20.57 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Intellia Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $137.84 Mil.

Intellia Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($176.85 Mil) to Dec. 2025 ($170.73 Mil) and declined from Dec. 2025 ($170.73 Mil) to Mar. 2026 ($137.84 Mil).

Intellia Therapeutics's annual Total Liabilities increased from Dec. 2023 ($250.81 Mil) to Dec. 2024 ($319.06 Mil) but then declined from Dec. 2024 ($319.06 Mil) to Dec. 2025 ($170.73 Mil).

Intellia Therapeutics Total Liabilities Related Terms

Intellia Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Total Liabilities Chart

Intellia Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

254.22

284.53

250.81

319.06

170.73

Intellia Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															206.24	183.64	176.85	170.73	137.84

71GF Score

Intellia Therapeutics Inc NTLA

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Intellia Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Intellia Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	103.884	+	(66.849	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	170.73

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	842.127	-	671.394
	=	170.73

Intellia Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	76.445	+	(61.395	+	7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	137.84

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	758.779	-	620.939
	=	137.84

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $137.84 Mil mean?

Intellia Therapeutics (NTLA) has a Total Liabilities of $137.84 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Intellia Therapeutics and its competitors.

Is Intellia Therapeutics' Total Liabilities too high?

Intellia Therapeutics' current Total Liabilities is $137.84 Mil. Overall, Intellia Therapeutics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Intellia Therapeutics' Total Liabilities compare to MLYS and VCEL?

Intellia Therapeutics' Total Liabilities of $137.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Intellia Therapeutics and its competitors. Intellia Therapeutics's current Total Liabilities is $137.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Intellia Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.57, compared to a current price of $17.56 — trading 14.6% below its estimated fair value. The current Total Liabilities is $137.84 Mil. Intellia Therapeutics' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Total Liabilities is $137.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $17.56 is trading 14.6% below its estimated GF Value™ of $20.57. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

Total Liabilities: $137.84 Mil
GF Value™: $20.57 vs. price of $17.56 (14.6% below fair value)
GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies MLYS VCEL NRIX PHVS BHVN IMNM AGIO ABCL KOD SLS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 0JBU:UK 38I:Germany

Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website https://www.intelliatx.com

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

71GF Score

Get the complete analysis for NTLA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.56

Price

$20.57

GF Value

View NTLA Analysis

See Total Liabilities data for all stocks →